Experts Opinions

Interview of VEIN CONSULT Program investigators

Video soon available

How will the VEIN CONSULT Program impact on daily practice?

By Pr E. Rabe

« Enhanced awareness of the disease in the general population will benefit patients, many of whom have never been diagnosed or treated. Data from Germany suggest that this may apply to approximately 50% of individuals with CVD. I hope that the program will encourage more physicians to adopt processes for earlier detection and management of CVD. If more patients receive effective treatment from the early stages with an agent such as Daflon 500 mg, we may be able to delay or prevent the progression of the disease and the developemnt of severe complications. Agents like Daflon 500 mg play an important role in this strategy thanks to its unique vein-specific anti-inflammatory action. »


is supported by an unrestricted grant from Servier research group
Terms of use - Cookies policy - Cookies management
Report a side-effect with a drug.

Access to this website is intended for the use of Healthcare Professionals only. By clicking the button "I agree" herebelow, you certify being a Healthcare Professional.